Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19

Sponsor
Tanta University (Other)
Overall Status
Completed
CT.gov ID
NCT04447534
Collaborator
(none)
191
1
2
1.7
109.7

Study Details

Study Description

Brief Summary

we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19.

Condition or Disease Intervention/Treatment Phase
  • Drug: Chloroquine or hydroxychloroquine
  • Drug: zinc
Phase 3

Detailed Description

we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19. As, zinc may be of value in these cases and may be of value in enhancing chloroquine effect.

Study Design

Study Type:
Interventional
Actual Enrollment :
191 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Treatment
Official Title:
Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19?
Actual Study Start Date :
Jun 23, 2020
Actual Primary Completion Date :
Jul 15, 2020
Actual Study Completion Date :
Aug 15, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Chloroquine or hydroxychloroquine

Chloroquine or hydroxychloroquine alone

Drug: Chloroquine or hydroxychloroquine
Chloroquine or hydroxychloroquine
Other Names:
  • alexoquine, chloroquine, hydroquine
  • Experimental: Chloroquine or hydroxychloroquine with zinc

    Chloroquine or hydroxychloroquine with zinc

    Drug: Chloroquine or hydroxychloroquine
    Chloroquine or hydroxychloroquine
    Other Names:
  • alexoquine, chloroquine, hydroquine
  • Drug: zinc
    Zinc tablets

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients with improvement or mortality [2 weeks]

      The number of patients with improvement or mortality.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with positive COVID-19.
    Exclusion Criteria:
    • Contraindications or hypersensitivity to chloroquine.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tanta university hospital, Assuit University, Ainshams University Tanta Egypt

    Sponsors and Collaborators

    • Tanta University

    Investigators

    • Principal Investigator: sherief Abd-Elsalam, Ass. Prof., ass. Prof. Tropical Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University
    ClinicalTrials.gov Identifier:
    NCT04447534
    Other Study ID Numbers:
    • tanta zinc chloroquine
    First Posted:
    Jun 25, 2020
    Last Update Posted:
    Apr 1, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 1, 2022